Repotrectinib Expands Treatment Options for Lung Cancers with ROS1 Fusions
Cancer Currents: An NCI Cancer Research Blog,
The results of the clinical trial that led to FDA’s 2023 approval of repotrectinib (Augtyro) for lung cancers with ROS1 fusions…